According to the Wise Finance APP, clinical stage biopharmaceutical company mustang bio (MBIO.US) closed up a staggering 476.92% on Monday, with a reported price of $0.75. On the news side, Mustang Bio announced positive data from its phase 1/2 trial of CAR-T cell therapy MB-106 for Waldenstrom's macroglobulinemia. The company said the data showed an overall response rate of 90%, with one patient achieving complete response at 31 months, all 10 patients enrolled in the trial had previously received treatment with BTKi therapy.

Mustang Bio pointed out that the US Food and Drug Administration (FDA) has not yet approved CAR-T cell therapy for Waldenstrom's macroglobulinemia. In addition, the company is working with Fred Hutchinson Cancer Center (Fred Hutch) to develop MB-106 for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma(B-NHL) and chronic lymphocytic leukemia (CLL).